Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.
Oncology, Medical November 13th 2023
Cancer Therapy Advisor
The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.
Oncology, Medical November 6th 2023
The New England Journal of Medicine
This phase 2 trial demonstrated that tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. With a manageable safety profile and no new safety signals identified, tarlatamab could represent a significant advancement in the treatment landscape for these patients.
Oncology, Medical October 23rd 2023
Explore how high-dose hyperfractionated thoracic radiotherapy is setting new standards in LS-SCLC treatment.
Oncology, Medical October 17th 2023
Oncology Learning Network
New research indicates that PCI offers significant survival advantages over TRT in treating extensive-stage small cell lung cancer, challenging existing treatment protocols.
Oncology, Medical October 2nd 2023
Explore the complexities of treating small cell lung cancer (SCLC) after platinum-based therapy failure, including insights into immune checkpoint inhibitors, the preference for lurbinectedin, and the potential of liquid biopsies. Join Dr. Misty Shields in understanding the challenges and opportunities in this evolving field.
Oncology, Medical August 21st 2023